Green Cross Lab Cell Corporation Net Assets
Green Cross Lab Cell Corporation net assets. Based on the latest financial reports, Green Cross Lab Cell Corporation (144510) has net assets worth ₩189.35 Billion KRW (≈ $128.32 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩335.22 Billion ≈ $227.17 Million USD) and total liabilities (₩145.87 Billion ≈ $98.85 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how fast is Green Cross Lab Cell Corporation growing its equity to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩189.35 Billion |
| % of Total Assets | 56.49% |
| Annual Growth Rate | 35.74% |
| 5-Year Change | -62.74% |
| 10-Year Change | 295.83% |
| Growth Volatility | 312.9 |
Net Assets of Green Cross Lab Cell Corporation (2015–2025)
Net assets of Green Cross Lab Cell Corporation from 2015 to 2025. This chart illustrates how Green Cross Lab Cell Corporation's net assets have evolved over time, based on quarterly financial data. See Green Cross Lab Cell Corporation (144510) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for Green Cross Lab Cell Corporation (2015–2025)
The table below shows the annual net assets of Green Cross Lab Cell Corporation from 2015 to 2025. For live market cap and overall valuation, see Green Cross Lab Cell Corporation market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩190.38 Billion ≈ $129.02 Million |
-58.41% |
| 2024-12-31 | ₩457.79 Billion ≈ $310.24 Million |
-15.46% |
| 2023-12-31 | ₩541.48 Billion ≈ $366.95 Million |
+0.56% |
| 2022-12-31 | ₩538.46 Billion ≈ $364.91 Million |
+5.37% |
| 2021-12-31 | ₩511.00 Billion ≈ $346.30 Million |
+983.32% |
| 2020-12-31 | ₩47.17 Billion ≈ $31.97 Million |
+7.08% |
| 2019-12-31 | ₩44.05 Billion ≈ $29.85 Million |
-7.69% |
| 2018-12-31 | ₩47.72 Billion ≈ $32.34 Million |
-1.25% |
| 2017-12-31 | ₩48.32 Billion ≈ $32.75 Million |
+0.47% |
| 2016-12-31 | ₩48.10 Billion ≈ $32.59 Million |
+436.82% |
| 2015-12-31 | ₩8.96 Billion ≈ $6.07 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Green Cross Lab Cell Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1037.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Green Cross Lab Cell Corporation Net Assets Breakdown (December 2025)
Green Cross Lab Cell Corporation net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩225.40 Billion | 120.93% |
| Total Equity | ₩186.39 Billion | 100.00% |
Green Cross Lab Cell Corporation Competitors by Market Cap
The table below lists competitors of Green Cross Lab Cell Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Odlewnie Polskie SA
WAR:ODL
|
$100.73 Million |
|
The Hi-Tech Gears Limited
NSE:HITECHGEAR
|
$100.77 Million |
|
Asia Pacific Satellite Inc
KQ:211270
|
$100.80 Million |
|
SaltX Technology Holding AB
ST:SALT-B
|
$100.80 Million |
|
Samyang Packaging
KO:272550
|
$100.68 Million |
|
Ulusoy Un Sanayi ve Ticaret AS
IS:ULUUN
|
$100.62 Million |
|
LINMON MEDIA LTD -000025
F:8MN
|
$100.61 Million |
|
Hiap Teck Venture Bhd
KLSE:5072
|
$100.61 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Green Cross Lab Cell Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 457,789,877,600 to 186,391,573,230, a change of -271,398,304,370 (-59.3%).
- Net loss of 272,858,866,660 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-272.86 Billion | -146.39% |
| Other Changes | ₩1.46 Billion | +0.78% |
| Total Change | ₩- | -59.28% |
Book Value vs Market Value Analysis
This analysis compares Green Cross Lab Cell Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.80x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 2.17x to 0.80x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩4557.21 | ₩9890.00 | x |
| 2017-12-31 | ₩4578.66 | ₩9890.00 | x |
| 2018-12-31 | ₩4521.62 | ₩9890.00 | x |
| 2019-12-31 | ₩4173.68 | ₩9890.00 | x |
| 2020-12-31 | ₩4469.37 | ₩9890.00 | x |
| 2021-12-31 | ₩34028.67 | ₩9890.00 | x |
| 2022-12-31 | ₩35857.41 | ₩9890.00 | x |
| 2023-12-31 | ₩35547.75 | ₩9890.00 | x |
| 2024-12-31 | ₩30464.21 | ₩9890.00 | x |
| 2025-12-31 | ₩12403.66 | ₩9890.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Green Cross Lab Cell Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -146.39%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -164.85%
- • Asset Turnover: 0.55x
- • Equity Multiplier: 1.63x
- Recent ROE (-146.39%) is below the historical average (-10.35%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 25.23% | 6.55% | 2.05x | 1.88x | ₩1.36 Billion |
| 2016 | 4.84% | 5.49% | 0.78x | 1.13x | ₩-2.48 Billion |
| 2017 | 2.19% | 2.31% | 0.83x | 1.15x | ₩-3.78 Billion |
| 2018 | 2.10% | 1.98% | 0.88x | 1.20x | ₩-3.77 Billion |
| 2019 | -5.17% | -3.93% | 0.85x | 1.55x | ₩-6.68 Billion |
| 2020 | 8.82% | 4.86% | 1.12x | 1.62x | ₩-556.92 Million |
| 2021 | 6.15% | 18.67% | 0.26x | 1.26x | ₩-19.68 Billion |
| 2022 | 4.53% | 10.32% | 0.35x | 1.26x | ₩-29.47 Billion |
| 2023 | -0.03% | -0.09% | 0.28x | 1.25x | ₩-53.58 Billion |
| 2024 | -16.14% | -42.36% | 0.30x | 1.26x | ₩-119.68 Billion |
| 2025 | -146.39% | -164.85% | 0.55x | 1.63x | ₩-291.50 Billion |
Industry Comparison
This section compares Green Cross Lab Cell Corporation's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $30,797,900,549
- Average return on equity (ROE) among peers: -21.70%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Green Cross Lab Cell Corporation (144510) | ₩189.35 Billion | 25.23% | 0.77x | $100.72 Million |
| NSN Co. Ltd (031860) | $22.70 Billion | -26.74% | 2.01x | $12.68 Million |
| JOONGANG DNM Co.Ltd (051980) | $12.98 Billion | 2.53% | 0.87x | $416.23 Million |
| GeneMatrix Inc (109820) | $15.25 Billion | -8.96% | 0.87x | $18.20 Million |
| Genoray Co. Ltd (122310) | $78.82 Billion | 18.17% | 0.26x | $24.70 Million |
| Optipharm.CO.LTD (153710) | $25.14 Billion | -9.69% | 0.56x | $41.61 Million |
| Cancer Rop Co. Ltd. (180400) | $21.56 Billion | 2.85% | 0.03x | $121.27 Million |
| Cytogen Inc (217330) | $17.92 Billion | -23.11% | 0.10x | $34.79 Million |
| Gencurix Inc (229000) | $12.00 Billion | -160.46% | 1.79x | $31.07 Million |
| P&K Skin Research Center Co. Ltd (347740) | $70.81 Billion | 10.07% | 0.05x | $35.45 Million |
About Green Cross Lab Cell Corporation
GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in Nove… Read more